Multiparticulate Drug Delivery


Book Description

Authored by leading experts from academia, users and manufacturers, this book provides an authoritative account of the science and technology involved in multiparticulate drug delivery systems which offer superior clinical and technical advantages over many other specialized approaches in drug delivery. The book will cover market trends, potential benefits and formulation challenges for various types of multiparticulate systems. Drug solubility, dose, chemistry and therapeutic indications as well as excipient suitability coupled with manufacturing methods will be fully covered. Key approaches for taste-masking, delayed release and extended release of multiparticulates systems are of significant interest, especially their in-vivo and in-vitro performance. In addition, the principles of scale-up, QbD, and regulatory aspects of common materials used in this technology will be explained, as well as recent advances in materials and equipment enabling robust, flexible and cost-effective manufacture. Case studies illustrating best practices will also make the book a valuable resource to pharmaceutical scientists in industry and academia.




Nanomedicine


Book Description

This volume comprehensively covers cancer, cardiovascular and the central nervous system of nanomedicine. With an international board of authors, this volume is split into sections that cover subjects such as diabetes and nanotechnology as potential therapy, and nanomedicines for inflammatory diseases.




PEGylated Protein Drugs: Basic Science and Clinical Applications


Book Description

PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development.




Hydrophilic Matrix Tablets for Oral Controlled Release


Book Description

This detailed volume addresses key issues and subtle nuances involved in developing hydrophilic matrix tablets as an approach to oral controlled release. It brings together information from more than five decades of research and development on hydrophilic matrix tablets and provides perspective on contemporary issues. Twelve comprehensive chapters explore a variety of topics including polymers (hypromellose, natural polysaccharides and polyethylene oxide) and their utilization in hydrophilic matrices, critical interactions impacting tablet performance, in vitro physical and imaging techniques, and microenvironmental pH control and mixed polymer approaches, among others. In one collective volume, Hydrophilic Matrix Tablets for Oral Controlled Release provides a single source of current knowledge, including sections of previously unpublished data. It is an important resource for industrial and academic scientists investigating and developing these oral controlled release formulations.




Macromolecular Anticancer Therapeutics


Book Description

In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by limiting the toxicity, by enhanced permeability and retention into tumors, by tumor targeting using tumor-specific antibodies, by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result, various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today, looking at the pace of research and current success in this field of macromolecular therapeutics, it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus, we believe that the subject of this book is very timely, and that the book will fill an unmet need in the market. This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus, in a nutshell, this book details the basics of cancer, and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists, pharmaceutical technologists, and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates, post-graduates and Ph.D. students in these fields.










Functional Chitosan


Book Description

Thanks to their unique properties, chitosan and chitosan-based materials have numerous applications in the field of biomedicine, especially in drug delivery. This book examines biomedical applications of functional chitosan, exploring the various functions and applications in the development of chitosan-based biomaterials. It also describes the chemical structure of chitosan and discusses the relationship between their structure and functions, providing a theoretical basis for the design of biomaterials. Lastly, it reviews chemically modified and composite materials of chitin and chitosan derivatives for biomedical applications, such as tissue engineering, nanomedicine, drug delivery, and gene delivery.




We Were Caught Unprepared


Book Description

This is a print on demand edition of a hard to find publication. The fact that the outcome of the 2006 Hezbollah-Israeli War was, at best, a stalemate for Israel has confounded military analysts. Long considered the most professional and powerful army in the Middle East, with a history of impressive military victories against its enemies, the Israeli Defense Forces (IDF) emerged from the campaign with its enemies undefeated and its prestige tarnished. This historical analysis of the war includes an examination of IDF and Hezbollah doctrine prior to the war, as well as an overview of the operational and tactical problems encountered by the IDF during the war. The IDF ground forces were tactically unprepared and untrained to fight against a determined Hezbollah force. ¿An insightful, comprehensive examination of the war.¿ Illustrations.




Hyperbaric Oxygen Therapy Indications


Book Description

The Undersea and Hyperbaric Medical Society (UHMS) is an international, non-profit organization serving over 2,400 members from more than 50 countries. The UHMS is the primary source of scientific information for diving and hyperbaric medicine physiology worldwide, the breadth of which is illustrated in the triennial report, Hyperbaric Oxygen Therapy Indications. With leading experts authoring chapters in their respective fields, this publication continues to provide the most current and up to date guidance and support for scientists and practitioners of hyperbaric oxygen therapy. Hyperbaric Oxygen Therapy Indications, currently in its thirteenth edition, has grown in size and depth to reflect the evolution of the literature on the approved use of hyperbarics from both a clinical practice standpoint and insurance coverage perspective. To date, the committee recognizes fourteen indications, including the new indication, idiopathic sudden sensorineural hearing loss. Additionally, this book continues to be used by the Centers for Medicare and Medicaid Services and other third party insurance carriers in determining payment for HBO2 services.